Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Shell PLC — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Shell PLC trades at $103.9 (market cap $290.47B). The key difference: Shell PLC is far larger — about 101.6× Dyne Therapeutics Inc. Common Stock's market cap, and Shell PLC pays a 3.03% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Shell PLC for 91 Days on average.
| DYN | SHEL | |
|---|---|---|
Market Cap | $2.86B | $290.47B |
Volume | 3,341,579 | 4,901,394 |
Sector | Health | Energy |
52-Week High | $26.78 | $103.58 |
52-Week Low | $14.60 | $70.31 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $2.18B | $332.17B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Shell (SHEL) trades at $103.58, up 1.96% today, near its consensus price target of $103.24. The stock shows bullish momentum with strong earnings beats in Q1 and Q2 2026, though Q4 2025 missed estimates. Recent news highlights expansion in LNG Canada Phase 2, doubling export capacity. Valuation metrics appear reasonable with a P/E of 11.39 and EV/EBITDA of 4.89. Operating cash flow remains robust at $42.86 billion for 2025, supporting dividend payments and strategic investments.
Outlook is positive with analyst consensus favoring Buy ratings (61.54%) and a high price target of $122.40. Key opportunities include LNG growth and portfolio optimization, while risks involve energy price volatility and execution of large-scale projects. The stock's current technical overbought condition may prompt near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
